Idarubicin 是一种有效的、具有口服活性的蒽环类抗白血病剂。Idarubicin 抑制拓扑异构酶 II，干扰 DNA 复制和 RNA 转录。Idarubicin 可诱导 DNA 损伤。Idarubicin 抑制DNA合成和c-Myc表达。Idarubicin 还抑制细菌和酵母菌的生长。

Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin was shown to induce DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts [1] [2] [3] [4] [5].

The IC 50 of idarubicin is 3.3 ± 0.4 ng/mL on MCF-7 monolayers and 7.9 ± 1.1 ng/mL in multicellular spheroids [1]. Idarubicin exhibits a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks [2]. Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively [3]. Idarubicin produces a concentration-dependent reduction in MCF-7 cell growth, with an IC 50 of approximately 0.01 μM. Idarubicin produces a concentration-dependent inhibition of DNA synthesis and a time- and concentration-dependent suppression of c-myc expression [4].

58957-92-9

C26H27NO9

497.49

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years